AQR Arbitrage’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

AQR Arbitrage’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-49,304	Closed	-$6.41K	–	842
2023 Q2	$6.41K	Sell	49,304 -60	-0.1%	-$5	﹤0.01%	764
2023 Q1	$2.02K	Sell	49,364 -634	-1%	-$49	﹤0.01%	1014
2022 Q4	$2.5K	Hold	49,998	–	–	﹤0.01%	1105
2022 Q3	$3K	Hold	49,998	–	–	﹤0.01%	1306
2022 Q2	$4K	Hold	49,998	–	–	﹤0.01%	1383
2022 Q1	$18K	Hold	49,998	–	–	﹤0.01%	1142
2021 Q4	$490K	Buy	+49,998	New	+$28.2K	0.01%	901

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

AQR Arbitrage's CLDI.WS Position: Q3 2023 in Review

AQR Arbitrage sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q3 2023, closing a stake of 49,304 shares — an estimated $6.41K sold.

AQR Arbitrage first reported a position in CLDI.WS in Q4 2021 and held it in 7 quarters. The position peaked at $490K in Q4 2021. 21 funds tracked by Wall St. Rank hold CLDI.WS as of Q3 2023.

AQR Arbitrage reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q3 2023 after selling out during the quarter.
AQR Arbitrage sold 49,304 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q3 2023, an estimated $6.41K.
AQR Arbitrage first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 7 quarters.
AQR Arbitrage's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $490K in Q4 2021.
21 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q3 2023.

Based on AQR Arbitrage's 13F filing for Q3 2023, filed 14 Nov 2023.